Health Dictionary Find a Doctor

Torsade de pointes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2]

Overview

Torsade de pointes, in French means “Twisting of the Points”. It is characterized by a polymorphic ventricular tachycardia and can occur in the congenital long QT syndromes, electrolyte abnormalities (hypomagnesemia, hypokalemia), usage of certain drugs like antiarrhythmic (quinidine), nonsedating antihistamines (terfenadine); antibiotics (erythromycin) and neuroleptics (thioridazine).

Historical Perspective

The term “torsade de pointes” was first described by Dessertenne in 1966, based on the characteristic “twisting” pattern of ventricular tachycardia seen on EKG.

Pathophysiology

Torsades de pointes is defined as the presence of polymorphic ventricular tachycardia with a prolonged QT segment on EKG. It is characterized by a constantly changing rhythm amplitude which comes from the ventricular depolarizing waves constantly shifting its axis. The underlying mechanism is thought to be triggered activity arising as a consequence of early after-depolarizations. During Torsade de pointes the ventricles depolarize in a circular fashion resulting in QRS complexes with a continuously turning heart axis around the baseline (hence the name Torsade de Pointes).

Causes

Common causes for torsades de pointes include hypomagnesemia and hypokalemia. It is commonly seen in malnourished individuals and chronic alcoholics. Drug interactions such as erythromycin or Avelox, taken concomitantly with inhibitors like nitroimidazole, diarrhea, dietary supplements, and various medications like methadone, lithium, tricyclic antidepressants or phenothiazines may also contribute to causing torsades de pointes.

Differentiating Torsades de pointes from other Conditions

Torsades de pointes should be differentiated from other conditions or disorders that may present in a similar way, such as other arrhythmias, drug toxicity, syncope and other cardiac conditions.

Risk Factors

Long QT syndrome is a risk factor for developing torsades de pointes, and can either be inherited as congenital mutations of ion channels carrying the cardiac impulse/action potential, or acquired as a result of drugs that block these cardiac ion currents. Other risk factors include electrolyte abnormalities, heart failure, left ventricular hypertrophy, female gender or renal and liver failure. Being on certain medications also pose a risk for developing torsades de pointes.

Natural History, Complications and Prognosis

Although Torsades de Pointes (TdP) is a rare ventricular arrhythmia, it can degenerate into ventricular fibrillation, leading to death without rapid medical intervention.

Diagnosis

History and Symptoms

Patients who are being evaluated for torsades de pointes should be asked about a history of syncope, and family history of long QT syndrome, sudden cardiac death, or sudden infant death syndrome. Torsades de pointes is associated with a fall in blood pressure, which often gives rise to syncopal symptoms. The patient may experience nausea, shortness of breath, dizziness,chest pain, and possibly ventricular fibrillation and sudden cardiac death.

Physical Examination

The physical exam during or directly after an episode of torsade de pointes, may reveal pallor and diaphoresis, loss of consciousness, and bradycardia followed by tachycardia.

Laboratory Findings

Laborotory tests obtained in a person with torsade de pointes will vary depending on the most likely etiology for their arrhythmia. Cardiac enzymes and levels of potassium, magnesium and calcium should be obtained.

Electrocardiogram

The EKG is the main diagnostic tool for torsades de pointes. EKG will show that the QRS complexes seem to twist around the horizontal isoelectric axis. Polymorphic ventricular tachycardia is distinguished from torsades de pointes by the absence of prolongation of the QT segment.

The ECG below is the characteristic tracing showing the “twisting” (blue line) of Torsade de pointes

Treatment

An understanding of the pathophysiology has led to development of treatment modalities like pacing, isoproterenol and drugs like magnesium and beta blockers.If the episode of does not terminate on its own and degenerates into ventricular fibrillation, cardioversion is required.

References

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The term “torsade de pointes” was first described by Dessertenne in 1966, based on the characteristic “twisting” pattern of ventricular tachycardia seen on EKG.

Historical Perspective

  • The French term is largely due to the fact that the phenomenon was originally described in a French medical journal by Dessertenne in 1966, when he observed this rhythm disorder in an 80-year-old female patient with complete intermittent atrioventricular block.
  • There has been much debate in the Circulation journal among French and American scientist whether one should write Torsades de Pointes or Torsade de Pointes.
  • As for now Torsade is prefered (unless one sees rotations around more than one axis in one episode), but both forms are used in similar frequency.[2]

References

  1. Dessertenne F (1966). “[Ventricular tachycardia with 2 variable opposing foci]”. Archives des maladies du coeur et des vaisseaux (in French). 59 (2): 263–72. PMID 4956181.
  2. Moise NS. As Americans, we should get this right. Circulation 1999 Sep 28; 100(13) 1462. PMID 10500317
Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.

Overview

Torsades de pointes is defined as the presence of polymorphic ventricular tachycardia with a prolonged QT segment on EKG. It is characterized by a constantly changing rhythm amplitude which comes from the ventricular depolarizing waves constantly shifting its axis. The underlying mechanism is thought to be triggered activity arising as a consequence of early after-depolarizations. During Torsade de pointes the ventricles depolarize in a circular fashion resulting in QRS complexes with a continuously turning heart axis around the baseline (hence the name Torsade de Pointes).

Pathophysiology

Torsade de pointes is characterized by constantly changing rhythm amplitude. ‘Torsade de pointes’ in French means “Twisting of the Points”. The changing rhythm amplitudes comes from the ventricular depolarizing waves constantly shifting its axis. It is usually caused by hypomagnesemia, hypokalemia, and malnourished alcoholics. Although Torsades de Pointes (TdP) is a rare ventricular arrhythmia, it can degenerate into ventricular fibrillation, leading to death without rapid medical intervention. TdP is associated with long QT syndrome, a condition whereby prolonged QT intervals are visible on the ECG.

Torsade de pointes is typically initiated by a short-long-short interval. A ventricular extrasystole (first beat: short) is followed by a compensatory pause. The following beat (second beat: long) has a longer QT interval. If the next beat follows shortly thereafter, there is a good chance that this third beat falls within the QT interval, resulting in the R on T phenomenon and subsequent Torsade de pointes. During Torsade de pointes the ventricles depolarize in a circular fashion resulting in QRS complexes with a continuously turning heart axis around the baseline (hence the name Torsade de Pointes).

Video: Torsade de pointes

{{#ev:youtube|1ccTO6fNobU}}

{{#ev:youtube|JDumoHHZocA}}

References

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Common causes for torsades de pointes include hypomagnesemia and hypokalemia. It is commonly seen in malnourished individuals and chronic alcoholics. Drug interactions such as erythromycin or Avelox, taken concomitantly with inhibitors like nitroimidazole, diarrhea, dietary supplements, and various medications like methadone, lithium, tricyclic antidepressants or phenothiazines may also contribute to causing torsades de pointes.

Causes

The List of Drugs that Cause Torsades de pointes

Drugs that are generally accepted to have a risk of causing torsades de pointes:

Drugs that Possibly Cause Torsades de pointes

Drugs that in some reports have been associated with torsades de pointes and/or QT prolongation but at this time lack substantial evidence for causing torsades de pointes.

The List of Drugs that Cause Torsades de pointes in Certain Conditions

Drugs that, in some reports, have been weakly associated with torsades de pointes and/or QT prolongation but that are unlikely to be a risk for torsades de pointes when used in usual recommended dosages and in patients without other risk factors (e.g., concomitant QT prolonging drugs, bradycardia, electrolyte disturbances, congenital long QT syndrome, concomitant drugs that inhibit metabolism)

Sources

http://www.qtdrugs.org/

References

Differentiating Torsades de pointes from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Torsades de pointes should be differentiated from other conditions or disorders that may present in a similar way, such as other arrhythmias, drug toxicity, syncope and other cardiac conditions.

Differential Diagnosis

The table below provides information on the differential diagnosis of torsades de pointes in terms of ECG appearance:

Disease Name Causes ECG Characteristics ECG view
Ventricular tachycardia [1][2][3][4][5]
[6]
Ventricular fibrillation [7][8][9][10]
[11]
Ventricular flutter [12][13][14]
[15]
Asystole [16][17]
  • There is no electrical activity in the asystole
[18]
Pulseless electrical activity [19][20]
[21]
Torsade de Pointes [22][23][24]
  1. Paroxysms of VT with irregular RR intervals.
  2. A ventricular rate between 200 and 250 beats per minute.
  3. Two or more cycles of QRS complexes with alternating polarity.
  4. Changing amplitude of the QRS complexes in each cycle in a sinusoidal fashion.
  5. Prolongation of the QT interval.
  6. Is often initiated by a PVC with a long coupling interval, R on T phenomenon.
  7. There are usually 5 to 20 complexes in each cycle.
[25]

References

  1. Ajijola, Olujimi A.; Tung, Roderick; Shivkumar, Kalyanam (2014). “Ventricular tachycardia in ischemic heart disease substrates”. Indian Heart Journal. 66: S24–S34. doi:10.1016/j.ihj.2013.12.039. ISSN 0019-4832.
  2. Meja Lopez, Eliany; Malhotra, Rohit (2019). “Ventricular Tachycardia in Structural Heart Disease”. Journal of Innovations in Cardiac Rhythm Management. 10 (8): 3762–3773. doi:10.19102/icrm.2019.100801. ISSN 2156-3977.
  3. Coughtrie, Abigail L; Behr, Elijah R; Layton, Deborah; Marshall, Vanessa; Camm, A John; Shakir, Saad A W (2017). “Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort”. BMJ Open. 7 (10): e016627. doi:10.1136/bmjopen-2017-016627. ISSN 2044-6055.
  4. El-Sherif, Nabil (2001). “Mechanism of Ventricular Arrhythmias in the Long QT Syndrome: On Hermeneutics”. Journal of Cardiovascular Electrophysiology. 12 (8): 973–976. doi:10.1046/j.1540-8167.2001.00973.x. ISSN 1045-3873.
  5. de Riva, Marta; Watanabe, Masaya; Zeppenfeld, Katja (2015). “Twelve-Lead ECG of Ventricular Tachycardia in Structural Heart Disease”. Circulation: Arrhythmia and Electrophysiology. 8 (4): 951–962. doi:10.1161/CIRCEP.115.002847. ISSN 1941-3149.
  6. ECG found in of https://en.ecgpedia.org/index.php?title=Main_Page
  7. Koplan BA, Stevenson WG (March 2009). “Ventricular tachycardia and sudden cardiac death”. Mayo Clin. Proc. 84 (3): 289–97. doi:10.1016/S0025-6196(11)61149-X. PMC 2664600. PMID 19252119.
  8. Maury P, Sacher F, Rollin A, Mondoly P, Duparc A, Zeppenfeld K, Hascoet S (May 2017). “Ventricular arrhythmias and sudden death in tetralogy of Fallot”. Arch Cardiovasc Dis. 110 (5): 354–362. doi:10.1016/j.acvd.2016.12.006. PMID 28222965.
  9. Saumarez RC, Camm AJ, Panagos A, Gill JS, Stewart JT, de Belder MA, Simpson IA, McKenna WJ (August 1992). “Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms”. Circulation. 86 (2): 467–74. doi:10.1161/01.cir.86.2.467. PMID 1638716.
  10. Bektas, Firat; Soyuncu, Secgin (2012). “Hypokalemia-induced Ventricular Fibrillation”. The Journal of Emergency Medicine. 42 (2): 184–185. doi:10.1016/j.jemermed.2010.05.079. ISSN 0736-4679.
  11. ECG found in https://en.ecgpedia.org/index.php?title=Main_Page
  12. Thies, Karl-Christian; Boos, Karin; Müller-Deile, Kai; Ohrdorf, Wolfgang; Beushausen, Thomas; Townsend, Peter (2000). “Ventricular flutter in a neonate—severe electrolyte imbalance caused by urinary tract infection in the presence of urinary tract malformation”. The Journal of Emergency Medicine. 18 (1): 47–50. doi:10.1016/S0736-4679(99)00161-4. ISSN 0736-4679.
  13. Koster, Rudolph W.; Wellens, Hein J.J. (1976). “Quinidine-induced ventricular flutter and fibrillation without digitalis therapy”. The American Journal of Cardiology. 38 (4): 519–523. doi:10.1016/0002-9149(76)90471-9. ISSN 0002-9149.
  14. Dhurandhar RW, Nademanee K, Goldman AM (1978). “Ventricular tachycardia-flutter associated with disopyramide therapy: a report of three cases”. Heart Lung. 7 (5): 783–7. PMID 250503.
  15. ECG found in https://en.ecgpedia.org/index.php?title=Main_Page
  16. ACLS: Principles and Practice. p. 71-87. Dallas: American Heart Association, 2003. ISBN 0-87493-341-2.
  17. ACLS for Experienced Providers. p. 3-5. Dallas: American Heart Association, 2003. ISBN 0-87493-424-9.
  18. ECG found in https://en.ecgpedia.org/index.php?title=Main_Page
  19. “2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care – Part 7.2: Management of Cardiac Arrest.” Circulation 2005; 112: IV-58 – IV-66.
  20. Foster B, Twelve Lead Electrocardiography, 2nd edition, 2007
  21. ECG found in wikimedia Commons
  22. Li M, Ramos LG (July 2017). “Drug-Induced QT Prolongation And Torsades de Pointes”. P T. 42 (7): 473–477. PMC 5481298. PMID 28674475.
  23. Sharain, Korosh; May, Adam M.; Gersh, Bernard J. (2015). “Chronic Alcoholism and the Danger of Profound Hypomagnesemia”. The American Journal of Medicine. 128 (12): e17–e18. doi:10.1016/j.amjmed.2015.06.051. ISSN 0002-9343.
  24. Khan IA (2001). “Twelve-lead electrocardiogram of torsades de pointes”. Tex Heart Inst J. 28 (1): 69. PMC 101137. PMID 11330748.
  25. ECG found in https://en.ecgpedia.org/index.php?title=Main_Page
Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Long QT syndrome is a risk factor for developing torsades de pointes, and can either be inherited as congenital mutations of ion channels carrying the cardiac impulse/action potential, or acquired as a result of drugs that block these cardiac ion currents. Other risk factors include electrolyte abnormalities, heart failure, left ventricular hypertrophy, female gender or renal and liver failure. Being on certain medications also pose a risk for developing torsades de pointes.

Risk Factors

Factors that are associated with an increased tendency toward torsades de pointes include:

Clinical Correlation

  1. Drugs: quinidine, PCA, norpace, amiodarone, phenothiazines, tricyclic antidepressants, pentamidine.
    • with quinidine majority of the cases occur within one week of initiation, and with therapeutic levels
  2. Electrolyte imbalances: hypokalemia, hypomagnesemia, hypocalcemia
  3. CAD
  4. MVP
  5. Variant angina
  6. Myocarditis
  7. Subarachnoid hemorrhage
  8. Congenital QT prolongation
  9. Liquid protein diets
  10. Hypothyroidism
    • because of bradycardia and a prolonged QT syndrome
  11. Organophosphate poisoning [1] [2]

References

  1. Chou’s Electrocardiography in Clinical Practice Third Edition, pp. 398-409.
  2. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:194 ISBN 1591032016
Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.

Overview

Although Torsades de Pointes (TdP) is a rare ventricular arrhythmia, it can degenerate into ventricular fibrillation, leading to death without rapid medical intervention. TdP is associated with long QT syndrome, a condition whereby prolonged QT intervals are visible on the ECG.

References

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | EKG Examples | Echocardiography | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Related Chapters


Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH